搜索

联系我们 / CONTACT US

地址:福州市仓山区进步路25号


 

0591-83441193

Copyright © 2022 福建省微生物研究所 版权所有 网站建设:中企动力福州  闽ICP备10006540 

地址:  福州市仓山区进步路25号    办公室电话:  0591-83441193、83476798  

科技管理科电话:  0591-83309157、83586273       传真:  0591-83441193   邮箱:  fim_cn@163.com

福建省微生物研究所

友情链接:  

用微信扫一扫

微信号
>
>
Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib

科研成果

SCIENTIFIC PAYOFFS

浏览量:

Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib

没有此类产品
产品描述
作者
Wei Huang;Qun-dan Wu;Min Zhang;Ying-li Kong;Pin-rong Cao;Wei Zheng;Jian-hua Xu;Min Ye*
刊物名称
Cancer Letters
2015
356
2
862-871

{Author}: Wei HuangQun-dan WuMin ZhangYing-li KongPin-rong CaoWei ZhengJian-hua XuMin Ye*

{Journal}: Cancer Letters

{Year}: 2015

{Volume}: 356

{Issue}: 2

{Pages}:862-871

{Keywords}: FW-04-806HER2HER3HER2-positive breast cancer

{Abstract}: Human epidermal growth factor receptor 2 (HER2), a member of the HER family of tyrosine kinases and a binding partner of Heat shock protein 90 (Hsp90), is found amplifies in approximately 25% breast cancers. Treatment of HER2+ breast cancers has been greatly improved in recent years, but the accompanying upregulation of HER3 induced by HER2 blockade has subdued the therapeutic effect. FW-04-806, a novel Hsp90 N-terminal inhibitor that disassociates the Hsp90/Cdc37/client complex and degrades Hsp90 clients, was studied alone or in combination with the EGFR/HER2 tyrosine kinase inhibitor lapatinib in HER2+ breast cancer cells. We found that FW-04-806 alone or with laptinib inhibits cell proliferation, induces cell apoptosis and reduces the total and activated HER3 levels in these cells, while lapatinib has been reported to increase HER3 expression followed HER2 inhibition. The combination of FW-04-806 and lapatinib showed synergistic reduction of HER2 expression and the downstream PI3K/Akt and Ras/MEK/ERK pathways, enhanced suppression of Akt-mediated FOXO3a inactivation and augmented antitumor efficacy on SKBR3 xenografts with a favorable toxicity profile, suggesting its viability as a combination therapy for clinical studies in HER2+ breast cancer patients.

未找到相应参数组,请于后台属性模板中添加
暂未实现,敬请期待
暂未实现,敬请期待
上一篇
下一篇

相关附件

暂时没有内容信息显示
请先在网站后台添加数据记录。